Alnylam shares tumble 30% even as biotech sector rallies
read at Endpoints ↗Negative
Alnylam's stock fell about 30% on July 28, 2026, even though the broader biotech market is experiencing a resurgence.
The market rebound follows years of a bearish environment, with increased merger activity and a surge in IPOs that are breaking records.
Despite these favorable industry trends, Alnylam remains an outlier, with analysts describing the company as one of the biggest mysteries in biopharma this year.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Alnylam's stock is down 30% despite a booming biotech market. Here's why”
read at Endpoints ↗83 words · retrieved Jul 28
comments(0)
5-min edit window · permanent after that